Viking Therapeutics Inc Stock Price, News & Analysis

Viking Therapeutics (VKTX) has reported its Q1 2025 financial results and provided key updates on its clinical pipeline. The company ended the quarter with a strong cash position of $852 million, down from $903 million in December 2024. The quarter saw a net loss of $45.6 million ($0.41 per share), compared to $27.4 million ($0.26 per share) in Q1 2024.

Key developments include:

• Phase 3 trials for subcutaneous VK2735 obesity treatment expected to begin in Q2 2025
• Completion of enrollment in Phase 2 VENTURE-Oral Dosing trial, with data expected in 2H 2025
• New manufacturing agreement with CordenPharma for VK2735 commercialization
• Advancement of novel amylin agonist program with IND filing planned for 2H 2025

R&D expenses increased to $41.4 million from $24.1 million year-over-year, while G&A expenses rose to $14.1 million from $10.0 million.

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has scheduled its first quarter 2025 financial results release for April 23, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss financial results and corporate updates. Participants can join via phone (U.S.: 844-850-0543; International: 412-317-5199) or through the company's website. A replay will be available until April 30, 2025, using access code #8779272.

Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.

The trial's primary endpoint focuses on body weight change after 13 weeks, with results expected in 2H25. Previous Phase 1 results showed promising outcomes, with weight reductions up to 8.2% after 28 days and up to 8.3% at follow-up. The drug demonstrated favorable safety profile with 99% of adverse events being mild or moderate.

Notably, Viking is also developing a subcutaneous formulation of VK2735, which showed significant results in its Phase 2 VENTURE study with weight reductions up to 14.7%. The company plans to initiate Phase 3 development for the subcutaneous formulation in 1H25.

Viking Therapeutics (VKTX) has entered a multi-year strategic partnership with CordenPharma for the development and manufacturing of its GLP-1 drug candidate VK2735. The partnership encompasses the full supply chain from drug substance to drug product for both subcutaneous and oral peptide formulations.

CordenPharma will provide large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance, along with fill-finish services for the subcutaneous formulation and oral solid dosage manufacturing. The agreement leverages CordenPharma's global network of manufacturing facilities, featuring built-in redundancy through multiple drug substance sites to ensure uninterrupted supply throughout the product lifecycle.

Viking Therapeutics (NASDAQ: VKTX) has secured a major manufacturing agreement with CordenPharma for its VK2735 obesity treatment program. The multi-year contract ensures dedicated production capacity for both subcutaneous and oral formulations to support potential multi-billion-dollar annual product sales.

The agreement includes:

• Annual production capacity for multiple metric tons of VK2735 API
• 100 million autoinjectors and 100 million vial/syringe products annually
• Over 1 billion oral tablets manufacturing capacity per year

Viking will make prepayments totaling $150 million between 2025-2028, which will be credited against future orders. The company maintains all global rights to VK2735 and expects standard pharmaceutical product margins. Currently, VK2735 is in Phase 2 VENTURE-Oral Dosing Trial, with Phase 3 development for the subcutaneous formulation planned for Q2 2025.

Viking Therapeutics (NASDAQ: VKTX) has announced its participation in two major upcoming investor conferences in March 2025. The company will attend the Leerink Partners Global Healthcare Conference 2025 from March 10-12, where management will engage in a fireside chat on March 11 from 9:20 to 9:50 a.m. Eastern, along with one-on-one meetings.

Additionally, Viking management will participate in the Jefferies Biotech on the Beach Summit from March 11-12, 2025, conducting one-on-one meetings. Both events will take place in Miami, FL. A live webcast of the Leerink presentation will be available through Viking's website in the Investors & Media section, with a replay accessible post-conference.

Viking Therapeutics (VKTX) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical pipeline. The company plans to initiate Phase 3 studies for its obesity treatment VK2735 in Q2 2025, following positive Phase 2 VENTURE study results showing up to 14.7% body weight reduction. A Phase 2 trial for an oral version of VK2735 is currently underway.

Financial highlights include a strong cash position of $903 million at year-end 2024. The company reported a Q4 net loss of $35.4 million ($0.32 per share) and full-year net loss of $110.0 million ($1.01 per share). R&D expenses increased to $101.6 million for 2024, up from $63.8 million in 2023.

Viking Therapeutics (NASDAQ: VKTX) has scheduled its fourth quarter and year-end 2024 financial results release for February 5, 2025, after market close. The clinical-stage biopharmaceutical company, which focuses on developing novel therapies for metabolic and endocrine disorders, will host a conference call at 4:30 p.m. Eastern Time on the same day.

Participants can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 internationally. A replay will be available until February 12, 2025, accessible by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (international) with replay code #6731266. The webcast will be available on Viking's website and archived for 30 days.

Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 2 VENTURE-Oral Dosing Trial for VK2735, their dual GLP-1 and GIP receptor agonist in tablet form. The 13-week study will evaluate safety, tolerability, pharmacokinetics, and weight loss efficacy in approximately 280 adults who are obese or overweight with comorbidities.

Previous 28-day Phase 1 results showed promising outcomes, with participants experiencing dose-dependent weight reductions up to 8.2%, and persistent effects up to 8.3% four weeks post-treatment. Up to 100% of treated subjects achieved ≥5% weight loss, compared to 0% for placebo. The treatment demonstrated good tolerability, with 99% of adverse events being mild or moderate.

Concurrently, Viking is advancing a subcutaneous formulation of VK2735, which showed significant results in its Phase 2 VENTURE study, with weight reductions up to 14.7%. The company plans to initiate Phase 3 development for the subcutaneous formulation in first half of 2025.